Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

FDA Grants Priority Review to Pembrolizumab as Adjuvant Therapy After Nephrectomy

By: JNCCN 360 Staff
Posted: Friday, August 13, 2021

On August 10, the U.S. Food and Drug Administration (FDA) granted Priority Review to a new supplemental biologics license application for pembrolizumab as an adjuvant treatment for certain patients with renal cell carcinoma. Pembrolizumab is intended to treat patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. The anti–PD-1 therapy has received prior approval for first-line treatment of patients with advanced renal cell carcinoma when combined with axitinib.

The decision for Priority Review comes after the FDA reviewed data from the double-blind phase III KEYNOTE-564 clinical trial. The study investigated pembrolizumab monotherapy for the adjuvant treatment in 994 patients with renal cell carcinoma who had a prior nephrectomy as well as have intermediate-high risk, high risk, or M1 no evidence of disease renal cell carcinoma with a clear cell component. The patients received either 200 mg of pembrolizumab intravenously on day 1 of each 3-week cycle for up to 17 cycles or a placebo.

The results showed a statistically significant and clinically meaningful improvement in disease-free survival when patients were given pembrolizumab compared with a placebo. For more information on the study data, visit meetinglibrary.asco.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.